Assays & Kits

The Spike Trimer (S1+S2) (B.1.617.2; Delta Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of  the interaction between SARS-CoV-2 Spike and human ACE2. The SARS-CoV-2 Spike Trimer, included in the kit, provides a biologically relevant model for the investigation of SARS-CoV-2/host cell interaction.  The assay requires only a few steps. First, Spike Trimer (S1+S2) (Delta Variant) (SARS-CoV-2) is coated on a 96-well plate overnight. After blocking, the protein is pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.

The Spike Trimer (S1+S2) (B.1.617.2.1; Delta Plus Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of  the interaction between SARS-CoV-2 Spike and human ACE2. The SARS-CoV-2 Spike Trimer, included in the kit, provides a biologically relevant model for the investigation of SARS-CoV-2/host cell interaction. The assay requires only a few steps. First, SARS-CoV-2 Spike Trimer is coated on a 96-well plate overnight.  After blocking, the protein is pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.

The Spike S1 RBD (B.1.617.2; Delta Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of  the interaction between SARS-CoV-2 Spike and human ACE2.  The assay requires only a few steps. First, Spike S1 RBD (B.1.617.2; Delta Variant) (SARS-CoV-2) is coated on a 96-well plate overnight. After blocking, the protein is pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.

The 3CL Protease (MERS-CoV) Inhibitor Screening Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. A protease inhibitor cocktail is included as a positive control. Assay Principle: 3CL Protease (MERS-CoV) Assay Kit uses a custom-synthesized peptide which has a fluorescence group quenched by a specific quencher. This peptide works as a substrate for 3CL Protease (MERS-CoV). After proteolytic cleavage, fluorescence product is formed and detected at λexcitation=485 nm and λemission=528 nm.

The Spike S1-Biotin (16-685) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

The Spike S1 (B.1.1.7; Alpha Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 (B.1.1.7; Alpha Variant) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

The Spike S1 (B.1.617.1; Kappa Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

The Spike S1 (P.1; Gamma Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (P.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

The CD38 (Mouse) Inhibitor Screening Assay Kit (Cyclase Activity) is designed to measure the cyclase activity of CD38 (mouse) for screening and profiling applications. The CD38 assay kit comes in a convenient 96-well format, with purified recombinant CD38 enzyme, its substrate nicotinamide guanine dinucleotide (NGD+), and CD38 assay buffer for 100 enzyme reactions. In addition, the kit includes the CD38 inhibitor quercetin for use as an inhibitor control.